Giesen

Researchers are evaluating the use of ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy as the first treatment for people with metastatic non-small cell lung cancer NSCLC. This Phase 3, randomized, double-blind, multiregional study involves around 1600 patients divided into two groups based on NSCLC histology squamous and non-squamous. The main goals are to assess overall survival and progression-free survival, with additional focus on treatment response and safety. Participants are randomly assigned to receive either ivonescimab or pembrolizumab along with platinum-doublet chemotherapy. Both treatments are given as intravenous injections. The two histology groups will be analyzed separately to understand how each treatment works within these subtypes of NSCLC. This design helps compare the effects of the two treatment combinations. During the study, participants will be monitored for survival and disease progression over several years. Safety assessments include tracking side effects from the start of treatment through 30 to 90 days after the last dose or start of other cancer therapies, with follow-up lasting up to two years. The study includes regular evaluations to measure tumor response and overall health, ensuring comprehensive monitoring throughout the participation period.

Researchers are evaluating ivonescimab as a first-line treatment for patients with metastatic non-small cell lung cancer NSCLC whose tumors show high PD-L1 expression. This phase 3 study compares ivonescimab to pembrolizumab, focusing on overall survival and progression-free survival to understand which treatment may better support patients with this condition. Participants will be randomly assigned to receive either ivonescimab or pembrolizumab through intravenous injection. The study is double-blinded and multiregional, involving continuous treatment and monitoring for up to approximately 36 months. Both groups receive their assigned treatment regularly during this period, with careful observation of treatment responses and side effects. During the trial, participants will undergo evaluations including scans to measure tumor size, laboratory tests, and assessments of adverse events. Researchers will track overall survival, progression-free survival, response rates, disease control, and duration of response. Safety monitoring will continue for up to 24 months after the last dose. The total study period extends until June 2029, allowing long-term data collection on treatment effects and safety.

Researchers are studying how well cabozantinib works and how safe it is for adults with neuroendocrine tumors NETs, a type of cancer that can develop in various parts of the body. All participants have previously received at least one systemic treatment for their cancer, but their disease has continued to progress. This observational study takes place in regular hospitals and clinics in Germany and Austria, involving about 150 participants. Participants receive cabozantinib as part of their usual medical care, without any extra tests or procedures beyond routine clinical practice. Doctors collect data from regular medical visits, scans, and tests to monitor how the cancer responds to treatment and how long participants stay on cabozantinib. The study also observes side effects and assesses quality of life using questionnaires over time. Throughout the study, participants undergo evaluations including scans and laboratory tests at baseline and every three months for up to 18 months. Researchers track outcomes such as disease control rate at 6 months, progression-free survival, treatment duration, side effects, and quality of life changes. The study follows participants until the end of 2028 to gather comprehensive information on the treatment course and patient experiences.